Cargando…
Perspective on the current state of the LRRK2 field
Almost 2 decades after linking LRRK2 to Parkinson’s disease, a vibrant research field has developed around the study of this gene and its protein product. Recent studies have begun to elucidate molecular structures of LRRK2 and its complexes, and our understanding of LRRK2 has continued to grow, aff...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314919/ https://www.ncbi.nlm.nih.gov/pubmed/37393318 http://dx.doi.org/10.1038/s41531-023-00544-7 |
_version_ | 1785067410437439488 |
---|---|
author | Taymans, Jean-Marc Fell, Matt Greenamyre, Tim Hirst, Warren D. Mamais, Adamantios Padmanabhan, Shalini Peter, Inga Rideout, Hardy Thaler, Avner |
author_facet | Taymans, Jean-Marc Fell, Matt Greenamyre, Tim Hirst, Warren D. Mamais, Adamantios Padmanabhan, Shalini Peter, Inga Rideout, Hardy Thaler, Avner |
author_sort | Taymans, Jean-Marc |
collection | PubMed |
description | Almost 2 decades after linking LRRK2 to Parkinson’s disease, a vibrant research field has developed around the study of this gene and its protein product. Recent studies have begun to elucidate molecular structures of LRRK2 and its complexes, and our understanding of LRRK2 has continued to grow, affirming decisions made years ago to therapeutically target this enzyme for PD. Markers of LRRK2 activity, with potential to monitor disease progression or treatment efficacy, are also under development. Interestingly, there is a growing understanding of the role of LRRK2 outside of the central nervous system in peripheral tissues such as gut and immune cells that may also contribute to LRRK2 mediated pathology. In this perspective, our goal is to take stock of LRRK2 research by discussing the current state of knowledge and critical open questions in the field. |
format | Online Article Text |
id | pubmed-10314919 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-103149192023-07-03 Perspective on the current state of the LRRK2 field Taymans, Jean-Marc Fell, Matt Greenamyre, Tim Hirst, Warren D. Mamais, Adamantios Padmanabhan, Shalini Peter, Inga Rideout, Hardy Thaler, Avner NPJ Parkinsons Dis Perspective Almost 2 decades after linking LRRK2 to Parkinson’s disease, a vibrant research field has developed around the study of this gene and its protein product. Recent studies have begun to elucidate molecular structures of LRRK2 and its complexes, and our understanding of LRRK2 has continued to grow, affirming decisions made years ago to therapeutically target this enzyme for PD. Markers of LRRK2 activity, with potential to monitor disease progression or treatment efficacy, are also under development. Interestingly, there is a growing understanding of the role of LRRK2 outside of the central nervous system in peripheral tissues such as gut and immune cells that may also contribute to LRRK2 mediated pathology. In this perspective, our goal is to take stock of LRRK2 research by discussing the current state of knowledge and critical open questions in the field. Nature Publishing Group UK 2023-07-01 /pmc/articles/PMC10314919/ /pubmed/37393318 http://dx.doi.org/10.1038/s41531-023-00544-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Perspective Taymans, Jean-Marc Fell, Matt Greenamyre, Tim Hirst, Warren D. Mamais, Adamantios Padmanabhan, Shalini Peter, Inga Rideout, Hardy Thaler, Avner Perspective on the current state of the LRRK2 field |
title | Perspective on the current state of the LRRK2 field |
title_full | Perspective on the current state of the LRRK2 field |
title_fullStr | Perspective on the current state of the LRRK2 field |
title_full_unstemmed | Perspective on the current state of the LRRK2 field |
title_short | Perspective on the current state of the LRRK2 field |
title_sort | perspective on the current state of the lrrk2 field |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314919/ https://www.ncbi.nlm.nih.gov/pubmed/37393318 http://dx.doi.org/10.1038/s41531-023-00544-7 |
work_keys_str_mv | AT taymansjeanmarc perspectiveonthecurrentstateofthelrrk2field AT fellmatt perspectiveonthecurrentstateofthelrrk2field AT greenamyretim perspectiveonthecurrentstateofthelrrk2field AT hirstwarrend perspectiveonthecurrentstateofthelrrk2field AT mamaisadamantios perspectiveonthecurrentstateofthelrrk2field AT padmanabhanshalini perspectiveonthecurrentstateofthelrrk2field AT peteringa perspectiveonthecurrentstateofthelrrk2field AT rideouthardy perspectiveonthecurrentstateofthelrrk2field AT thaleravner perspectiveonthecurrentstateofthelrrk2field |